(Q28219095)

2

0 references

Gianfranco Calogiuri

3

0 references

Fabio Calcagnile

4

0 references

Eugenio Quarta

5

0 references

Maurizio Muratore

6

0 references

Antonio Ferrannini

Annals of Allergy, Asthma & Immunology

7

0 references

language of work or name

English

0 references

publication date

February 2007

0 references

published in

0 references

volume

98

0 references

issue

2

0 references

page(s)

168-71

0 references

cites work

Association of chronic urticaria with thyroid autoimmunity and Raynaud phenomenon with anticentromere antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

Aspirin sensitivity and urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

Sulfidoleukotriene release test (CAST) in hypersensitivity to nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

Clinical pharmacology of novel selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

Tolerability of rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021

Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960691-6

7 January 2021